Ocugen, Inc. logo

Ocugen, Inc.

NASDAQ:OCGN

Overview | Financials
Company Name Ocugen, Inc.
Symbol OCGN
Currency USD
Price 1.63
Market Cap 419,643,500
Dividend Yield 0%
52-week-range 0.345 - 2.105
Industry Biotechnology
Sector Healthcare
CEO Dr. Shankar Musunuri M.B.A., MBA, Ph.D.
Website https://www.ocugen.com

An error occurred while fetching data.

About Ocugen, Inc.

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis;

Related Stocks

AirSculpt Technologies, Inc. logo

AirSculpt Technologies, Inc.

AIRS

4.53 USD

Seer, Inc. logo

Seer, Inc.

SEER

1.81 USD

PetMed Express, Inc. logo

PetMed Express, Inc.

PETS

4.08 USD

Janux Therapeutics, Inc. logo

Janux Therapeutics, Inc.

JANX

47.6 USD

OptimizeRx Corporation logo

OptimizeRx Corporation

OPRX

12.15 USD

MaxCyte, Inc. logo

MaxCyte, Inc.

MXCT

4.68 USD

Affimed N.V. logo

Affimed N.V.

AFMD

4.02 USD

Y-mAbs Therapeutics, Inc. logo

Y-mAbs Therapeutics, Inc.

YMAB

12.27 USD

Financials

Numbers are in millions USD

Numbers are in millions USD